Evidence map›Paper›PMID 41158876›Full record

ReviewFrontiers in molecular biosciences2025

ARF: the most misunderstood GTPase I ever knew - why study ARF GAPs.

Rachel E Turn, Joel Bryan Dacks, Eric M Rosenberg, Olivier Soubias, John K Northup, Paul A Randazzo

Abstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel E TurnDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, United States.
Joel Bryan DacksDepartment of Medicine, University of Alberta, Edmonton, AB, Canada.
Eric M RosenbergLaboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD, United States.
Olivier SoubiasLaboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD, United States.
John K NorthupNational Cancer Institute, Bethesda, MD, United States.
Paul A RandazzoLaboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ADP-ribosylation factors (ARFs) are GTP-binding proteins that were discovered in the early 1980s, shortly after heterotrimeric GTP-binding proteins (G proteins) and nearly simultaneously with RAS. G proteins formed the basis for the signaling paradigm that has been broadly applied to GTPases, including both RAS and ARF. In this paradigm, GTP-binding proteins act as switches. When converted from the GDP-bound form to the GTP-bound form, GTPases bind effector proteins to transduce a signal. This paradigm is consistent, at least in part, with RAS function as RAS•GTP activates effectors to drive cellular responses such as proliferation. ARF, on the other hand, functions outside this paradigm, at least in its first discovered physiological role: regulation of membrane traffic. Nevertheless, ARFs are often generalized as "on" and "off" switches controlling signaling pathways. In this study, we (i) briefly describe the history of the discoveries of three families of GTPases to provide an understanding of the genesis of the G-protein signaling model, (ii) enumerate some key differences between ARFs, RAS, and G proteins (which better fit the paradigm of molecular switches), and (iii) describe an alternate model for ARFs, in which their cycling between GTP binding and hydrolysis mediates cellular activities, rather than ARFs acting as mediators in a signaling cascade. Furthermore, we highlight the key role of GTPase-activating proteins (GAPs) as integral to ARF function.

Indexed as

ADP-ribosylation factorARFG proteinGTPaseGTPase-activating proteinP loop NTPaseRAS

Identifiers

PMID41158876
PMCPMC12554972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.